PIM
CASI

Penobscot Investment Management’s CASI Pharmaceuticals CASI Stock Holding History

Penobscot Investment Management’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,700
Closed -$113K – 197
2018
Q1 		$113K Buy
+2,700
New +$101K 0.03% 199
2017
Q1 		– Sell
-2,700
Closed -$31K – 180
2016
Q4 		$31K Buy
+2,700
New +$37K 0.01% 180

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $666M AUM 45.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Penobscot Investment Management's CASI Position: Q2 2018 in Review

Penobscot Investment Management sold out of CASI Pharmaceuticals (CASI) in Q2 2018, closing a stake of 2,700 shares — an estimated $113K sold.

Penobscot Investment Management first reported a position in CASI in Q4 2016 and held it in 2 quarters. The position peaked at $113K in Q1 2018. 57 funds tracked by Wall St. Rank hold CASI as of Q2 2018.

  • Penobscot Investment Management reported no remaining CASI Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Penobscot Investment Management sold 2,700 CASI Pharmaceuticals shares in Q2 2018, an estimated $113K.
  • Penobscot Investment Management first reported a position in CASI Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Penobscot Investment Management's CASI Pharmaceuticals position peaked at $113K in Q1 2018.
  • 57 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2018.

Based on Penobscot Investment Management's 13F filing for Q2 2018, filed 7 Aug 2018.